RELATED PRODUCTS NOT AVAILABLE
true
{"AlternateComparison":false,"RelatedProducts":false,"Specification":true,"FeatureBenefit":false}
BD Onclarity™
BD Onclarity™ HPV Assay
![Icon to close thank you modal]()
BD Viper™ Neutralization Pouch
Support
Becton Dickinson Australia & New Zealand
AU: 1800 656 100
NZ: 0800 572 468
Thank you for contacting our sales team!
A sales representive will get in touch with you shortly.
For more information, please visit our Contact Us page
- Overview
- Specifications
- eIFUs and Resources
- FAQ
The BD Onclarity™ HPV assay with extended genotyping offers the flexibility you need to adapt to changing screening guidelines and evolving patient management guidance.
In the post-vaccination era the prevalence of high-risk genotypes may change making it crucial to identify high-risk genotypes individually.
- Extended genotyping supports risk stratification and persistence monitoring to guide patient management1-5
- Genotypes 16 and 18 account for 70% of invasive cancer worldwide, but their prevalence is declining as vaccination rates increase.6-9
- Genotypes 31,33,58 have a CIN3+ risk similar to genotype 18, but 51,35,39,68,56,59,66 have a much lower risk.10-11
true
FEATURE AND BENEFIT CARDS NOT AVAILABLE
FEATURE AND BENEFIT CARDS NOT AVAILABLE
GTIN - Shelfpack
30382904413546
12
GTIN - Each
00382904413545
1
Quantity - Shelfpack
12
GTIN
| GTIN - Shelfpack | 30382904413546 | 12 |
| GTIN - Each | 00382904413545 | 1 |
Packaging
| Quantity - Shelfpack | 12 |
false
false
true